

بسم الله الرحمن الرحيم





شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار





بعض الوثائق الأصلية تالفة





بالرسالة صفحات
لم ترد بالأصل



B1A.15

Benha University
Faculty of Veterinary Medicine
Department of Virology

Trials for using Wheat Germ Oil as adjuvant in inactivated Rift Valley Fever Virus Vaccine

Hamdy Lamy Nasralla

Microbiology Diploma, Cairo Univ., 1990
Master Degree, Virology, Zagazig Univ, 2000

For the Degree of
Ph.D. V.Sc., **Virology**

Under Supervision of

Prof. Dr. Gabr El-Bagoury

Prof. of Virology,
And Head of Department of virology
Faculty of Veterinary Medicine
Benha University

Prof. Dr.

Ahmed M. Daoud

Chief Researcher, Veterinary Serum
and Vaccine Research Institute,
Abbasia, Cairo

Prof. Dr.

Khairat A.A. Elan

Chief Researcher, Veterinary Serum
and Vaccine Research Institute,
Abbasia, Cairo

2006



Benha University,
Faculty of Veterinary Medicine,
Department of Virology

APPROVAL SHEET

This is to approve that the dissertation presented by:

Hamdy Lamy Nasralla

to Benha University entitled:

**Trials for using Wheat Germ Oil as adjuvant in inactivated
Rift Valley Fever Virus Vaccine**

for the degree of Ph.D. in Veterinary Science (Virology) has been approved in
9/7/2006 by the examining committee:

MEMBERS

SIGNATURE

*** Prof. Dr. Mohamed Mahmoud Taha**

Director of Central Laboratory for evaluation of Veterinary
Biologics, Abbasia, Cairo

Dr. M. M. Taha

*** Prof. Dr. Ahmed Abdou Ali El-Sawalhy**

Professor of Infectious Diseases and Head of Animal Medicine Dept.
Faculty of Veterinary Medicine
Mansoura University

El-Sawalhy
A A

*** Prof. Dr. Gabr El-Bagoury**

Prof. of Virology,
And Head of Department of virology
Faculty of Veterinary Medicine
Benha University
(Supervisor)

G. El-Bag

*** Prof. Dr. Khairat A.A. Elia**

Chief Researcher, Veterinary Serum and Vaccine
Research Institute, Abbasia, Cairo
(Supervisor)

Dr. Khairat Elia

Date: 9/7/2006




Vaccine Research Institute, Abbasia, Cairo, for his great support.

I would like to offer my great thanks to Prof. Dr. Gihan Kamal Mohamed, Head of RVF Department, Veterinary Serum and Vaccine Research Institute, Abbasia, Cairo, for facilities to carry out this work.

I would like to offer my thanks to staff members of RVF Department, Veterinary Serum and Vaccine Research Institute, Abbasia, Cairo, who helped me during this work and specially Dr. Taimor Naseif, Dr. Eman Shalakamy, Dr. Lilly Sobhy, Dr. Alfons Mina, Dr. Tarady and Dr. Karin EldimZaki.


Cardial thanks to my mother, my wife and my daughters for their patience.





List of Contents

	Page
1. INTRODUCTION	1
2. REVIEW OF LITERATURE	4
2.1. History and Geographic	4
Distribution of the disease	4
2.1.1. In the world	9
2.1.2. In Egypt	11
2.2. Rift Valley Fever virus	11
2.2.1. Classification	12
2.2.2. Morphology	14
2.2.3. Physicochemical properties	15
2.2.4. Biological properties	15
2.2.4.1. Haemagglutination activity	16
2.2.4.2. Susceptibility for tissue culture	17
2.2.4.3. Antigenic properties	18
2.2.4.4. Interference phenomenon	20
2.2.5. Virus strains	21
2.2.6. Virus stability	22
2.3. Virus transmission and mode of	22
infection	25
2.4. Susceptibility to different	25
animals	25
2.4.1. Sheep	26
2.4.2. Goats	27
2.4.3. Cattle	



	Page
2.4.4. Camels	28
2.4.5. Mice and rats	29
2.4.6. Bats	30
2.4.7. Rhesus Monkeys	30
2.4.8. Wild ruminants	30
2.5. Laboratory Diagnosis	31
2.5.1. Samples for virus isolation	31
2.5.2. Virus isolation	32
2.5.3. Serological tests	34
2.5.3.1. Enzyme linked immunosorbent assay (ELISA)	34
2.5.3.2. Serum neutralization test (SNT)	35
2.6. Rift Valley Fever vaccines	36
2.6.1. Inactivated Rift Valley Fever vaccine	36
2.6.1.1. RVF alum inactivated vaccine	36
2.6.1.2. RVF oil inactivated vaccine	39
2.6.2. Attenuated vaccine	42
2.7. Immunostimulant agent	44
2.7.1. Role of vitamin E in immune response	44
3. MATERIAL AND METHODS	46
3.1. Material	46
3.1.1. Virus	46
3.1.1.1. Virulent RVF virus (ZH-501)	46
3.1.2. Tissue culture cell	46
3.1.3. Experimental animals	46



	Page
3.1.3.1. Sheep	46
3.1.3.2. Laboratory animals	47
3.1.4. Biological reagents	47
3.1.4.1. RVF antigen	47
3.1.4.2. Bovine serum	47
3.1.4.3. Anti-sheep IgG serum conjugated with horseradish peroxidase	48
3.1.5. Media and solutions	48
3.1.5.1. Growth media	48
3.1.5.2. Maintenance media	48
3.1.5.3. Trypsin versin solution (0.5%)	48
3.1.5.4. Antibiotic solution	49
3.1.5.5. Bicarbonate solution	49
3.1.5.6. Merthiolate	49
3.1.5.7. Hydrochloric acid solution	49
3.1.5.8. Alhydrogel	49
3.1.5.9. Germ wheat oil	50
3.1.5.10. Span 80	50
3.1.5.11. 2-Bromoethyleneimine hydrobromide	50
3.1.5.12. Sodium hydroxide solution	50
3.1.5.13. Sodium thiosulphate solution	50
3.1.6. Reagents used for ELISA	51
3.1.6.1. Tween-20	51
3.1.6.2. Phosphate buffer solution (PBS)	51
3.1.6.3. Substrate buffer	51
3.1.6.4. Stopping buffer	52





	Page
3.1.6.5. Washing buffer	52
3.1.6.6. Blocking buffer	52
3.1.6.7. Coating buffer	52
3.1.6.8. Diluting buffer	52
3.1.7. ELISA plates	53
3.1.8. Microplate tissue cultures	53
3.2. Methods.	54
3.2.1. Analysis of germ wheat oil	54
3.2.2. Propagation of RVF virus (ZH-501)	54
3.2.3. Infectivity titration of RVF virus	55
3.2.3.1. In tissue culture	55
3.2.3.2. In adult mice	55
3.2.4. Safety of the adjuvant	55
3.2.5. Inactivation of the virus by BEI	56
3.2.6. Preparation of different types of vaccine	56
3.2.6.1. Preparation of alum gel inactivated RVF vaccine	56
3.2.6.2. Preparation of inactivated RVF oil vaccine (wheat germ oil)	56
3.2.7. Evaluation of the vaccine	57
3.2.7.1. Sterility test	57
3.2.7.2. Safety test	57
3.2.7.3. Potency in mice	58
3.2.8. Experimental Design	59
3.2.8.1. Vaccination of animal group	59
3.2.8.2. Collection of serum samples and swabs	60
3.2.9. RVF reisolation	61



3.2.9.1. From serum samples	61
3.2.9.2. From swabs	61
3.2.10. Serological analysis	61
3.2.10.1. Serum neutralization test (SNT)	61
3.2.10.2. Enzyme linked immunosorbent assay (ELISA)	62
3.2.11. Shelf life of RVF oil vaccine	64
3.2.11.1. Physical appearance	64
3.2.11.2. Potency test	64
4. RESULTS	65
5. DISCUSSION	111
6. SUMMARY	119
7. REFERENCES	121
ARABIC SUMMARY	

List of Tables

Table	Title	Page
1	Infectivity titration of RVF virus on BHK cells and mice	65
2	Toxic effect of germ wheat oil in adult mice	66
3	Sterility test on prepared vaccines in different types of media	67
4	Safety test of prepared vaccines in weaned mice	68
5	Safety test of the two prepared vaccines in lambs	68
6	The potency test of the prepared vaccine	69
7	Potency of oil RVF vaccine at zero time (Time of preparation at 4°C)	71
8	Potency of new oil RVF vaccine after 3 months of preparation and preserved at 4°C	72
9	Potency of new oil RVF vaccine after 6 months of preparation and preserved at 4°C	73
10	Potency of new oil RVF vaccine after 8 months of preparation and preserved at 4°C	74
11	Potency of new oil RVF vaccine after 9 months of preparation and preserved at 4°C	75
12	Potency of new oil RVF vaccine after 10 months of preparation and preserved at 4°C	76
13	Potency of new oil RVF vaccine after 11 months of preparation and preserved at 4°C	77
14	Potency of new oil RVF vaccine after 12 months of preparation and preserved at 4°C	78